# RedHill Biopharma Ltd.: overview RDHL · Nasdaq · CIK 1553846 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/rdhl.md) · [Financials](/companies/rdhl/financials.md) · [Filings](/companies/rdhl/filings.md) · [Insiders](/companies/rdhl/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [64.4](/filings/0001558370-23-007149.md) | [85.8](/filings/0001558370-24-004806.md) | [61.8](/filings/0001558370-25-004648.md) | [6.5](/filings/0001558370-25-004648.md) | [8.0](/filings/0001558370-25-004648.md) | | Gross margin | % | [42.7%](/filings/0001558370-23-007149.md) | [42.4%](/filings/0001558370-24-004806.md) | [46.1%](/filings/0001558370-25-004648.md) | [47.0%](/filings/0001558370-25-004648.md) | [60.3%](/filings/0001558370-25-004648.md) | | Operating margin | % | [(99.0%)](/filings/0001558370-23-007149.md) | [(94.6%)](/filings/0001558370-24-004806.md) | [(69.3%)](/filings/0001558370-25-004648.md) | [193.4%](/filings/0001558370-25-004648.md) | [(181.7%)](/filings/0001558370-25-004648.md) | | Net margin | % | [(118.4%)](/filings/0001558370-23-007149.md) | [(114.0%)](/filings/0001558370-24-004806.md) | [(116.0%)](/filings/0001558370-25-004648.md) | [366.2%](/filings/0001558370-25-004648.md) | [(102.8%)](/filings/0001558370-25-004648.md) | | Diluted EPS | $ per share | [(0.21)](/filings/0001558370-23-007149.md) | [(0.21)](/filings/0001558370-24-004806.md) | [(0.12)](/filings/0001558370-25-004648.md) | [0.01](/filings/0001558370-25-004648.md) | [0.00](/filings/0001558370-25-004648.md) | | Free cash flow | $m | [(49.0)](/filings/0001558370-23-007149.md) | [(65.2)](/filings/0001558370-24-004806.md) | [(29.4)](/filings/0001558370-25-004648.md) | [(35.8)](/filings/0001558370-25-004648.md) | [(9.4)](/filings/0001558370-25-004648.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rdhl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Yorkville Advisors Global, LP](/funds/1838613.md) | 2026-06-30 | $106.7k | 122,131 | | Reduced −228,739 | | [GAGNON SECURITIES LLC](/funds/1125725.md) | 2026-06-30 | $74.7k | 88,405 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $55.2k | 65,321 | | Added +44,648 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $11.6k | 13,755 | | Added +8,639 | | [Lido Advisors, LLC](/funds/1650150.md) | 2026-06-30 | $9.3k | 11,009 | | New +11,009 | | [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $5.9k | 6,957 | | Added +273 | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $3.7k | 4,378 | | New +4,378 | | [Federation des caisses Desjardins du Quebec](/funds/2022297.md) | 2026-06-30 | $2.9k | 3,388 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $85 | 100 | | Reduced −726 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $13 | 15 | | Added +11 | ## Recent filings [All 1,029 filings](/companies/rdhl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 11:00 ET | [6-K](/filings/0001178913-26-004808.md) | Report of a foreign private issuer, period 2026-10-21 | 0001178913-26-004808 | | 2026-10-19 | 12:02 ET | [6-K](/filings/0001178913-26-004786.md) | Report of a foreign private issuer, period 2026-10-19 | 0001178913-26-004786 | | 2026-10-13 | 20:10 ET | [6-K](/filings/0001178913-26-004765.md) | Report of a foreign private issuer, period 2026-10-13 | 0001178913-26-004765 | | 2026-10-07 | 12:00 ET | [6-K](/filings/0001178913-26-004732.md) | Report of a foreign private issuer, period 2026-10-07 | 0001178913-26-004732 | | 2026-09-30 | 20:23 ET | [6-K](/filings/0001178913-26-004678.md) | Report of a foreign private issuer, period 2026-09-30 | 0001178913-26-004678 | | 2026-09-30 | 20:11 ET | [6-K](/filings/0001104659-26-112334.md) | Report of a foreign private issuer, period 2026-06-30 | 0001104659-26-112334 | | 2026-09-01 | 11:10 ET | [6-K](/filings/0001178913-26-004369.md) | Report of a foreign private issuer, period 2026-09-01 | 0001178913-26-004369 | | 2026-08-31 | 11:03 ET | [6-K](/filings/0001178913-26-004329.md) | Report of a foreign private issuer, period 2026-08-31 | 0001178913-26-004329 | | 2026-08-07 | 13:03 ET | [6-K](/filings/0001178913-26-003929.md) | Report of a foreign private issuer, period 2026-08-07 | 0001178913-26-003929 | | 2026-08-06 | 13:00 ET | [6-K](/filings/0001178913-26-003906.md) | Report of a foreign private issuer, period 2026-08-06 | 0001178913-26-003906 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-049055.md), filed Apr 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1553846 - Tickers: RDHL - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: L3 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.